company-logo

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Kura Oncology Dividend Announcement

Kura Oncology does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
Stay tuned for updates on Kura Oncology dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Kura Oncology Dividend History

Kura Oncology Dividend Yield

Kura Oncology current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Kura Oncology stock? Use our calculator to estimate your expected dividend yield:

Kura Oncology Financial Ratios

P/E ratio-4.82
PEG ratio2.65
P/B ratio2.25
ROE-44.09%
Payout ratio0.00%
Current ratio11.47
Quick ratio11.47
Cash Ratio1.23

Kura Oncology Dividend FAQ

Does Kura Oncology stock pay dividends?
Kura Oncology does not currently pay dividends to its shareholders.
Has Kura Oncology ever paid a dividend?
No, Kura Oncology has no a history of paying dividends to its shareholders. Kura Oncology is not known for its dividend payments.
Why doesn't Kura Oncology pay dividends?
There are several potential reasons why Kura Oncology would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Kura Oncology ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Kura Oncology has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Kura Oncology a dividend aristocrat?
Kura Oncology is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Kura Oncology a dividend king?
Kura Oncology is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Kura Oncology a dividend stock?
No, Kura Oncology is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Kura Oncology stocks?
To buy Kura Oncology you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Kura Oncology stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.